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Abstract
Background: The prognosis of gastric cancer patients is difficult to predict because of defects in establishing the 
surgical-pathological features. Cancer-associated fibroblasts (CAFs) have been found to play prominent role in 
promoting tumor growth, invasion and metastasis. Thus raises the hypothesis that the extent of CAFs prevalence may 
help to establish the prognosis of gastric cancer patients.
Methods: Immunochemistry and realtime-PCR experiments were carried out to compare the expression of proteins 
which are specific markers of CAFs or secreted by CAFs in the tumor and normal tissue specimens. The extent of CAFs' 
prevalence was graded according to immunochemical staining, and correlation was further analyzed between CAFs' 
prevalence and other tumor characteristics which may influence the prognosis of gastric cancer patients.
Results: Nearly 80 percent of normal gastric tissues were negative or weak positive for CAFs staining, while more than 
60 percent of gastric cancer tissues were moderate or strong positive for CAFs staining. Realtime-PCR results also 
showed significant elevated expression of FAP, SDF-1 and TGF-β1 in gastric cancer tissues compared to normal gastric 
tissues. Further analysis showed that CAFs' prevalence was correlated with tumor size, depth of the tumor, lymph node 
metastasis, liver metastasis or peritoneum metastasis.
Conclusions: Reactive cancer associated fibroblasts (CAFs) were frequently accumulated in gastric cancer tissues, and 
the prevalence of CAFs was correlated with tumor size, depth of the tumor and tumor metastasis, thus give some 
supports for establishing the prognosis of the gastric cancer patients.
Background
Gastric cancer is the second leading cause of cancer-
related death worldwide [1]. Substantial geographic vari-
ations exist in the incidence of gastric cancer and it repre-
sents the most common cancer in China [2]. More and
more gastric cancer patients have been diagnosed in
recent years with changing diet and lifestyle as well as
developing diagnostic procedures. Although surgical
treatment has shown to be effective for some early gastric
cancers, including total gastrectomy and extended radical
gastrectomy, the prognosis of these patients is poor due
to the recurrence after surgery, in the form of lymphatic
spread, blood-borne metastasis, or peritoneal dissemina-
tion [3].
The prognosis of patient with gastric cancer has been
shown to be influenced by several established surgical-
pathological features, such as the pathological stage, the
location of the tumor and the histological type and grade
of the tumor [4]. While Aurello et al. [5] have indicated
that the number of nodes necessary to conclude N0 may
vary according to the depth of tumor invasion (T), the
TNM classification requires the retrieval and analysis of
at least 15 lymph nodes for accurate staging. However, in
most cases, the number of nodes dissected is smaller and
only 20 to 30% of the patients have the recommended
minimum dissection of 15 nodes. Accessorial indicators
which can provide further information of the prognosis
of gastric cancer patients are needed.
Cancer-associated fibroblast (CAF), one of the impor-
tant stromal cells comprising solid tumors, has been
found to play prominent role in promoting tumor growth
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and progression [6]. In contrast to resting fibroblasts,
CAFs possess an activated phenotype and can be identi-
fied by their expression of fibroblast-specific protein 1
(FSP1), vimentin, desmin, and α-smooth-muscle actin
[7]. CAFs communicate among themselves as well as with
cancer cells and inflammatory and immune cells directly
through cell contact and indirectly through paracrine/
exocrine signaling, proteases, and modulation of the
extracellular matrix (ECM). This complex communica-
tions network is pivotal to providing the appropriate
microenvironment to support tumorigenesis, angiogene-
sis, and metastasis [8,9]. Additionally, compared to trans-
formed tumor cells, CAFs are more genetically
homogeneous [10] and it has been demonstrated by
Gastavo et al that reactive stroma can act as a predictor of
recurrence in prostate cancer [11], thus represent an
attractive predictor and therapeutic target for tumor
patients.
In this study, we collected 100 cases of surgical resec-
tion specimens of primary gastric cancer as well as nor-
mal gastric tissues (more than 5 cm far from tumor
tissue) from January 2007 to June 2007 in the Second Mil-
itary Medical University affiliated Changhai hospital
(Shanghai, China). Immunochemistry and RT-PCR
experiments were carried out to compare the expression
of proteins which are specific markers of CAFs or
secreted by CAFs in the tumor and normal tissue speci-
mens. The extent of CAFs' prevalence was graded accord-
ing to immunochemical staining, and correlation was
further analyzed between CAFs' prevalence and other
tumor characteristics which may influence the prognosis
of gastric cancer patients.
Methods
Cohort Enrollment
One hundred cases of primary gastric cancer patients
were enrolled from January 2007 to June 2007 in the Sec-
ond Military Medical University affiliated Changhai hos-
pital. All patients have provided a written informed
consent. Entry criteria for this study include: (a) no pre-
operative chemotherapy treatment; (b) pathologically or
cytologically validated gastric-adenocarcinoma; (c) aged
between 18-85 years; (d) expected life>3 months; (e)
WBC>3.5×109/L; PLT>1011/L; Hb>100 g/L; Serum crea-
tinine no more than 1.25 times of normal upper limit;
GPT and ALP no more than 1.25 times of normal upper
limit; Total bilirubin no more than 1.5 times of normal
upper limit; PT<12s; and (f) no severe CNS disease.
Pathological analysis
All specimens including tumor tissues and normal gastric
tissues which was more than 5 cm far from tumor tissues
were fixed in 10% formalin within 30 minutes after surgi-
cal resection. Paraffin embedded serial sections (4 μm)
were prepared. Tumor differentiation was characterized
according to WHO classification (2000) while the TNM
classification was done according to International Union
Against Cancer, fifth edition (1997).
Immunochemistry
Antibody used in this procedure includes rabbit anti-
FSP1 polyclonal antibody (Abcam, 1:50), mouse anti-α-
SMA monoclonal antibody (Sigma, 1A4, 1:200), rat anti-
procollagen I monoclonal antibody (Chemicon,
Mab1912, 1:500), biotin-conjugated rat anti-mouse IgG
polyclonal antibody (ebioscience, 13-4013, 1:100), biotin-
conjugated mouse anti-rat IgG polyclonal antibody (ebio-
science, 13-4813, 1:100) and biotin-conjugated mouse
anti-rabbit IgG polyclonal antibody (BD PharMingen,
C101-167, 1:100). Immunochemistry analysis was per-
formed as previously described [12]. Briefly, paraffin sec-
tions were de-paraffinized in xylene and a series of
graded alcohol solutions. The sections were then treated
with 0.3% hydrogen peroxide (H2O2) in water for 10
minutes to quench any endogenous peroxidase activity
within the tissue, and the nonspecific binding sites were
blocked with 0.5% bovine serum albumin (BSA) for 10
minutes at room temperature. Next, the sections were
incubated for 15 minutes in the presence of the primary
antibody, and then the slides were washed in phosphate
buffered saline (PBS) containing 0.1% Tween 20 (PBS/
Tween) for 15 minutes while changing the solution 3
times before the application of the secondary biotinylated
antibody. The slides were incubated with the secondary
antibody for 15 minutes at room temperature before
being washed for 15 minutes in PBS/Tween that was
changed 3 times. The sections were then incubated for 15
minutes with an avidin-biotinylated horseradish peroxi-
dase complex, and the reaction visualized using 0.02%
3,3'-diaminobenzidine tetrahydrochloride as a chromo-
gen in a Tris-HCl buffer, pH 7.6, containing 0.03% H2O2.
Hematoxylin was used to counterstain the nuclei.
Histological analysis
To evaluate the level of FSP1, α-SMA and procollagen-I
expression, the percentage of positive-staining cells were
graded on a scale of 0-3, with less than 5% positive-stain-
ing cells as grade 0, 5-25% as grade 1, 26-50% as grade 2,
and more than 50% as grade 3. And the intensity of stain-
ing also graded on a scale of 0-2, with negative to weak
intensity as grade 0, weak to moderate intensity as grade
1, and moderate to strong intensity as grade 2. Ten high-
power fields were selected randomly for each slides and
analyzed by two pathologists independently. For each
marker, the score of percentage and intensity was multi-
plied and the scores for these three markers was added
when these markers was analyzed conjointly. And the
final score between 0-6 was determined as negative (-),Zhi et al. Journal of Experimental & Clinical Cancer Research 2010, 29:66
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score between 7-9 was determined as weak positive (+),
score between 10-12 was determined as moderate posi-
tive (++), and score higher than 13 was determined as
strong positive (+++).
Realtime-PCR
Total RNA was extracted from tumor or normal tissues
by Trizol reagent (invitrogen) and first-strand cDNA was
synthesized using RevertAid First Strand cDNA Synthesis
Kit (Fermentas, USA) as described previously [13]. Real-
time PCR was carried out using LightCycler DNA Master
SYBR Green I Kit (Roche Diagnostics, Mannheim, Ger-
many) according to the manufacturer's instructions. The
c o p i e s  o f  t a r g e t  c D N A  w e r e  n o r m a l i z e d  b y  G A P D H
expression. Primers for FAP, SDF-1, TGF-β1 and GAPDH
were listed as follows:
FAP F: 5'-TGGGAATATTACGCGTCTGTCTAC-3'
FAP R: 5'-GATAAGCCGTGGTTCTGGTCA-3'
SDF-1 F: 5'-CCGTCAGCCTGAGCTACA-3'
SDF-1 R: 5'-GAAGGGCACAGTTTGGAG-3'
TGF-β1 F: 5'-GCAACAATTCCTGGCGATAC-3'
TGF-β1 R: 5'-AAGGCGAAAGCCCTCAAT-3'
GAPDH F: 5'-ATCAAGTTGCGTGCTGTG-3'
GAPDH R: 5'-TGCGAAATGAAAGGAGTGT-3'
For each target cDNA, the copies of normal tissue sam-
ples is averaged, and the copies of each tumor tissue sam-
ple is divided by the average, then the results of these
three target cDNA is added for each tumor tissue sample.
If the sum is equal to or larger than 8, then the tumor tis-
sue is considered to be positive for CAFs.
Statistical analysis
Data are shown as means and standard deviations. Statis-
tical analyses of the data were analyzed with the two-
tailed independent Student's t test and χ2 analysis by SPSS
12.0. The level of statistical significance was set at P <
0.05.
Results
Reactive tumor associated fibroblasts were prevalent in 
gastric cancer tissues
To determine the extent of CAFs' prevalence in gastric
cancer tissues, paraffin embedded sections of tissue spec-
imens were prepared and stained for FSP1, α-SMA and
procollagen I expression as described above. In addition,
realtime-PCR was carried out to determine the expres-
sion level of several proteins which was expressed or
secreted by reactive CAFs, such as FAP, SDF-1 and TGF-
β1.
Results of immunochemistry staining showed that
more reactive fibroblasts were present in gastric cancer
tissues than normal gastric tissues. Twenty four out of the
100 normal specimens were negative (-) for reactive
fibroblasts staining and 55 normal specimens were weak
positive (+). And the number of normal specimens which
were moderate (++) or strong positive (+++) were 21 and
0, respectively. While concerning cancer tissues, there
were 13, 26, 25 and 36 specimens which were negative (-),
weak positive (+), moderate positive (++) and strong pos-
itive (+++) for fibroblast staining, respectively (Fig 1a and
Fig 1b). And if tumor specimens graded as negative or
weak positive were regarded as negative, and moderate or
strong positive were regarded as positive, there was a sig-
Figure 1 Immunochemistry analysis of the grade of CAFs' preva-
lence in tumor and normal gastric tissues. Paraffin sections of surgi-
cally resected tumor and normal tissues from the same gastric cancer 
patients (100 cases) were stained for FSP1, α-SMA and procollagen-1 
expression and CAFs prevalence was graded according to the positive 
rate and intensity of the immunochemical staining. The number of tu-
mor or normal tissue specimens graded as -, +, ++ and +++ was com-
pared (a). And the distribution of these four grades of CAFs' prevalence 
in the 100 tumor or normal tissue specimens were analyzed (b). Grade 
- and + was regarded as negative, while grade ++ and +++ was regard-
ed as positive for CAFs prevalence, then the number of the tumor or 
normal tissue specimens which was positive or negative for CAFs' 
prevalence was compared (c).Zhi et al. Journal of Experimental & Clinical Cancer Research 2010, 29:66
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nificant difference between tumor and normal tissues
concerning the positive rate of CAFs (Fig 1c).
For mRNA expression of the proteins, results showed
that the expression level of all these proteins were ele-
vated in tumor specimens compared to these in normal
tissues. Taking FAP as an example, the mRNA expression
level of FAP in tumor specimens was 4 times higher than
t h a t  i n  n o rm a l  t i s s u e s  ( F i g  2 a ) .  A n d  t h e r e  w e r e  a ls o  3
times elevation of mRNA expression level regarding SDF-
1 (Fig 2b) or TGF-β1 (Fig 2c).
From these results, we can conclude that reactive CAFs
were prevalent in gastric tumor tissues and secret high
level of proteins which have been demonstrated to be
essential for tumor growth, invasion and metastasis.
CAFs' prevalence was closely related with invasive and 
metastatic properties of gastric tumor
To determine whether the grade of CAFs' prevalence can
be served as a predictor for the prognosis of gastric can-
cer patients, correlation analysis was carried out between
the grade of CAFs' prevalence and other clinicopathologi-
cal parameters of gastric cancers. Tumor specimens
graded as negative or weak positive were regarded as neg-
ative, and moderate or strong positive were regarded as
positive in these analysis. Patient and tumor characteris-
tics were described in Table 1. We can also find in Table 1
that there was no correlation between CAFs' prevalence
and age, gender of the patient or the location of the
tumor. There was an increase of CAFs' prevalence when
the tumor differentiation decreased from well-differenti-
ated (43.75%) to poorly-differentiated (64.00%), while the
positive rate of CAFs in undifferentiated gastric cancer is
only 26.67%, much less than that in well or poorly differ-
entiated gastric cancers, thus we could not find the corre-
lation between the CAFs' prevalence and tumor
differentiation (P = 0.56). While concerning tumor size,
depth of the tumor (T) and lymph node metastasis (N),
there showed statistically significant correlation between
the prevalence of CAFs and these tumor characteristics,
with higher positive rate of CAFs in larger tumors, more
invasive tumors and tumors with more lymph node
metastasis. Also we can find that the positive rate of
CAFs was high in gastric cancers with liver metastasis (P
< 0.01) or peritoneum metastasis (P < 0.01).
In addition, in the situation of tumor metastasis, what-
ever lymph node metastasis, distant metastasis or organ
metastasis, the positive percentage for CAFs is much
higher than that in those without metastasis (71.93% vs
25.58%, P < 0.01) (Fig 3).
And we also analyzed the correlation between the
mRNA level of FAP, SDF-1 and TGF-β1 and the gastric
cancer stage. The level of these proteins were scored as
described in the methods and the tumor tissue samples
were determined to be positive if the score is equal to or
larger than 8. It was found that the positive percentage is
much high in large tumors (>5 cm, 32/38) than that in
small tumors (≤5 cm, 20/62) (p < 0.05). And the positive
percentage in tumor samples with TNM stage IA, IB, II,
IIIA, IIIB and IV are 33.3% (5/15), 42.9%(3/7), 52.6%(10/
19), 60.9%(14/23), 73.3%(11/15) and 76.2(16/21), respec-
tively, showing that the prevalence of CAFs is closely cor-
related with the gastric cancer stages (p < 0.01). These
results strongly suggested that CAFs' prevalence could
help to establish the gastric cancer stage and could be
used as a marker for the prognosis of gastric cancer
patients.
Discussion
Recent studies in molecular and cellular biology have
shown that tumor growth and metastasis are not deter-
mined by cancer cells alone but also by a variety of
stromal cells [14,15]. The stroma actively provides con-
tinuous support to carcinoma cells throughout the differ-
ent pathophysiological processes that modulate tumor
progression. Fibroblasts are an important component of
tumor stroma, which have received increased attention
because of their participation in tumor development,
including growth, invasion and metastasis, such as in
prostate cancer [16,17] or breast cancer [18,19]. It has
also been demonstrated in a gastric cancer mice model
that activated fibroblasts promote tumor angiogenesis
[20], and it is consistent with out results that activated
Figure 2 Realtime-PCR analysis of secreted proteins by CAFs in 
tumor and normal gastric tissues. Total RNA was extract and cDNA 
was prepared from surgically resected tumor and normal tissues from 
the same gastric cancer patients (100 cases). Realtime-PCR was carried 
out to compare the expression level of FAP (a), SDF-1 (b) and TGF-β1 
(c) in tumor and normal tissues, the first two lanes of the electrophore-
togram represented normal tissues and the last two lanes represented 
tumor tissues. *:p < 0.01.Zhi et al. Journal of Experimental & Clinical Cancer Research 2010, 29:66
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Table 1: Patient and tumor characteristics and their relationship with CAFs prevalence
N Positive for CAFs N (%) P value
Age (year) 2.77a
≤60 47 22 (46.81)
>60 53 29 (54.72)
Sex 5.11a
Male 57 32 (56.14)
Female 43 19 (44.19)
Location of the tumor 1.35b
Proximal end of stomach (1/3) 13 9 (69.23)
Gastric body (1/3) 19 9 (47.37)
Remote end of stomach (1/3) 51 22 (43.14)
More than 1/3 of the stomach involved 17 11 (64.71)
Tumor differentiation 0.56b
Well differentiated 16 7 (43.75)
Moderate differentiated 44 24 (54.55)
Poorly differentiated 25 16 (64.00)
Undifferentiated 15 4 (26.67)
Tumor size 0.02a
≤5 cm 62 16 (35.48)
>5 cm 38 29 (76.32)
Depth of tumor (T) 0.03b
Tis 4 1 (25.00)
T1 13 5 (38.46)
T2 39 19 (48.72)
T3 26 15 (57.69)
T4 18 11 (61.11)
Lymph node metastasis (N) <0.01a
N0 46 16 (34.78)
N1-3 54 35 (64.81)
Liver metastasis <0.01a
Yes 12 9
No 88 42
Peritoneum metastasis <0.01a
Yes 9 7 (77.77)
No 91 44 (48.35)
TNM Stage <0.01b
IA 15 3 (20)
IB 7 2 (28.57)
II 19 6 (31.58)
IIIA 23 11 (47.83)
IIIB 15 8 (53.33)
IV 21 14 (66.67)
a: Fisher exact test; b: Chi-Square TestsZhi et al. Journal of Experimental & Clinical Cancer Research 2010, 29:66
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fibroblasts were accumulated in human gastric cancer tis-
sues.
The term fibroblast encompasses a number of stromal
cells with a broadly similar phenotype. Most tumors
incorporate an obvious biologically active, fibroblastic
cell type known variously as reactive fibroblasts, myofi-
broblasts, or simply tumor-associated fibroblasts.
Smooth muscle α-actin (α-SMA) is the most common
marker used to identify CAFs, while its expression can
also be found in smooth muscle cells and myoepithelial
cells [21]. So other markers should be used in combina-
tion with α-SMA to identify CAFs. Fibroblast-specific
protein 1 (FSP1, S100A4), a member of the family of
Ca2+ -binding S100 proteins, constitutively expressed in
the cytoplasm of tissue fibroblasts, and its expression is
highly specific for fibroblasts [22,23]. It is widely accepted
to combine a-SMA and FSP1 for the identification of
tumor-associated fibroblasts. And in our experiment, we
also used a third marker, procollagen I, to identify reac-
tive CAFs with production of extracellular matrix compo-
nents.
We also detected the mRNA expression level of other
proteins which is expressed or secreted by CAFs. FAP is a
type II transmembrane cell surface protein belonging to
the post-proline dipeptidyl aminopeptidase family, with
dipeptidyl peptidase and endopeptidase activity, includ-
ing a collagenolytic activity capable of degrading gelatin
and type I collagen [24,25]. FAP is expressed selectively
by CAFs and pericytes in more than 90% of human epi-
thelial cancers examined [26-30] and research has been
reported in animal model showing a therapeutic effect by
inhibiting FAP expression or enzymatic activity [31]. The
n e x t  p r o t e i n  w e  s e l e c t e d  t o  d e t e c t  i s  S D F - 1 ,  w h i c h  i s
secreted by CAFs and stimulates tumor cells prolifera-
tion, angiogenesis, invasion and metastasis through the
CXCR4 receptor expressed by tumor cells [32-34].
Another secreted protein we detected is TGF-β1, which is
a potent inducer for myofibroblasts differentiation [35],
and may play a role in tumor invasion-metastasis cas-
cades [36]. The results of the present study showed that
these proteins were up-regulated in gastric cancer tissues,
suggesting their potential role in promoting gastric can-
cer progression.
Gastric cancer is the second leading cause of cancer-
associated mortality in the world. Prognosis in patients
with gastric cancer is difficult to establish because it is
commonly diagnosed when gastric wall invasion and
metastasis have occurred. Several groups attempted to
find some biomarkers for the prognosis of gastric cancer.
For example, the expression of several extracellular
matrix metalloproteinases (MMP-2, 7, 9) has been found
to be elevated in gastric cancer tissues compared to
healthy gastric tissues. And the up-regulation of these
MMPs in gastric cancer has been associated with a poor
prognosis and elevated invasive capacity [37]. Another
e x a m p l e  i s  i n s u l i n - l i k e  g r o w t h  f a c t o r - 1  r e c e p t o r  ( I G F -
1R), it was frequently expressed in gastric cancers and
was associated with tumor size, quantity of stroma, depth
of wall invasion, lymph node metastasis, TNM stages and
differentiation status of gastric cancer [38]. And VEGF-C
expression at tumor margins was also associated with
nodal metastasis, lymphatic vessel invasion, poor recur-
rence-free survival, and poor overall survival, and could
serve as an independent predictor for patients with gas-
tric carcinoma [39]. We can find that these predictors are
either proteins secreted by CAFs or receptors expressed
by tumor cells which bind the proteins secreted by CAFs,
so these clues may suggest that the prevalence of CAFs in
gastric cancer tissues will be an important predictor of
gastric cancer patients. And our results confirmed that
the prevalence of CAFs was closely associated with the
Figure 3 The percentage of tumor specimens which was positive 
or negative for CAFs' prevalence in the group of patients with or 
without tumor metastasis. The tumor specimens were grouped ac-
cording to whether or not the gastric cancer patients had tumor me-
tastasis (whatever lymph node metastasis, distant metastasis or organ 
metastasis). And the percentage of the specimens which was positive 
(grade - or + according to immunochemical staining) or negative 
(grade ++ or +++ according to immunochemical staining) for CAFs' 
prevalence was analyzed (a). And the immunochemical staining of α-
SMA was shown in normal gastric tissue, gastric cancer tissue without 
metastasis and gastric cancer tissue with metastasis (b).Zhi et al. Journal of Experimental & Clinical Cancer Research 2010, 29:66
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metastatic potential of gastric cancer, and further work
should be done to confirm the correlation between CAFs'
prevalence and survival of gastric cancer patients.
Conclusions
Our findings report here demonstrate that reactive can-
cer associated fibroblasts (CAFs) were frequently accu-
mulated in gastric cancer tissues, and the prevalence of
CAFs was correlated with tumor size, depth of the tumor
and tumor metastasis as well as the overall TNM stage,
suggesting that CAFs were critical for tumor growth,
invasion and metastasis, thus give some supports for the
prognosis of the gastric cancer patients.
Abbreviations
CAFs: tumor associated fibroblasts; FAP: fibroblast activation protein; SDF-1:
stromal-cell derived factor 1; TGF-β1: transforming growth factor beta 1; ECM:
extracellular matrix; WBC: white blood cell count; PLT: platelet count; Hb:
hemoglobin; GPT: glutamic-pyruvic transaminase; ALP: alkaline phosphatase;
PT: prothrombin time; CNS: central nerves system; α-SMA: α-smooth-muscle
actin; FSP1: fibroblast specific protein 1; GAPDH: glyceraldehyde phosphate
dehydrogenase; MMP: matrix metalloproteinase; VEGF: vascular endothelial
growth factor.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
KK Zhi carried out the specimen collection and immunochemistry experiment.
XJ Shen dealed with RNA extraction and realtime PCR. H Zhang carried out the
statistical analysis. JW Bi designed the study and helped to draft the manu-
script. All authors have read and approved the final manuscript.
Acknowledgements
We want to thank Prof. Li Gao in the Department of pathology of Changhai 
Hospital and Dr. Ni Zhu in the Central Lab of Changhai Hospital for their expert 
technical supports for the experiments. This work was supported by The 
National Natural Science Foundation of China (30672046).
Author Details
Department of General Surgery, the Second Military Medical University 
affiliated Changhai hospital, Shanghai 200433, China
References
1. Anderson C, Nijagal A, Kim J: Molecular markers for gastric 
adenocarcinoma: an update.  Mol Diagn Ther 2006, 10:345-352.
2. Townsend CM Jr, Beauchamp RD, Evers BM, Mattox KL: Sabiston 
Textbook of Surgery.  18th edition. Saunders, An Imprinter of Elsevier. 
Philadelphia; 2008. 
3. Kim JW, Hwang I, Kim MJ, Jang SJ: Clinicopathological characteristics 
and predictive markers of early gastric cancer with recurrence.  J 
Korean Med Sci 2009, 24:1158-1164.
4. Miyahara R, Niwa Y, Matsuura T, Maeda O, Ando T, Ohmiya N, Itoh A, 
Hirooka Y, Goto H: Prevalence and prognosis of gastric cancer detected 
by screening in a large Japanese population: data from a single 
institute over 30 years.  J Gastroenterol Hepatol 2007, 22:1435-1442.
5. Aurello P, D'Angelo F, Rossi S, Bellagamba R, Cicchini C, Nigri G, Ercolani G, 
De Angelis R, Ramacciato G: Classification of lymphnode metastases 
from gastric cancer: comparison between N-site and N-number 
systems. Our experience and review of the literature.  Am Surg 2007, 
73:359-366.
6. Kalluri R, Zeisberg M: Fibroblasts in cancer.  Nat Rev Cancer 2006, 
6:392-401.
7. Mueller MM, Fusenig NE: Friends or foes - bipolar effects of the tumour 
stroma in cancer.  Nat Rev Cancer 2004, 4:839-849.
8. Bhowmick NA, Neilson EG, Moses HL: Stromal fibroblasts in cancer 
initiation and progression.  Nature 2004, 432:332-337.
9. Tlsty TD, Coussens LM: Tumor stroma and regulation of cancer 
development.  Annu Rev Pathol 2006, 1:119-150.
10. Qiu W, Hu M, Sridhar A, Opeskin K, Fox S, Shipitsin M, Trivett M, Thompson 
ER, Ramakrishna M, Gorringe KL, Polyak K, Haviv I, Campbell IG: No 
evidence of clonal somatic genetic alterations in cancer-associated 
fibroblasts from human breast and ovarian carcinomas.  Nat Genet 
2008, 40:650-655.
11. Ayala G, Tuxhorn JA, Wheeler TM, Frolov A, Scardino PT, Ohori M, Wheeler 
M, Spitler J, Rowley DR: Reactive stroma as a predictor of biochemical-
free recurrence in prostate cancer.  Clin Cancer Res 2003, 9:4792-4801.
12. Lee SJ, Kim JG, Sohn SK, Chae YS, Moon JH, Kim SN, Bae HI, Chung HY, Yu 
W: No Association of Vascular Endothelial Growth Factor-A (VEGF-A) 
and VEGF-C Expression with Survival in Patients with Gastric Cancer.  
Cancer Res Treat 2009, 41:218-223.
13. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR: 
Carcinoma-associated fibroblasts direct tumor progression of initiated 
human prostatic epithelium.  Cancer Res 1999, 59:5002-5011.
14. Bissell MJ, Radisky D: Putting tumours in context.  Nat Rev Cancer 2001, 
1:46-54.
15. Polyak K, Haviv I, Campbell IG: Co-evolution of tumor cells and their 
microenvironment.  Trends Genet 2009, 25:30-38.
16. Hayward SW, Wang Y, Cao M, Hom YK, Zhang B, Grossfeld GD, Sudilovsky 
D, Cunha GR: Malignant transformation in a nontumorigenic human 
prostatic epithelial cell line.  Cancer Res 2001, 61:8135-8142.
17. Cheng N, Bhowmick NA, Chytil A, Gorksa AE, Brown KA, Muraoka R, 
Arteaga CL, Neilson EG, Hayward SW, Moses HL: Loss of TGF-beta type II 
receptor in fibroblasts promotes mammary carcinoma growth and 
invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated 
signaling networks.  Oncogene 2005, 24:5053-5068.
18. Cheng N, Chytil A, Shyr Y, Joly A, Moses HL: Enhanced hepatocyte 
growth factor signaling by type II transforming growth factor-beta 
receptor knockout fibroblasts promotes mammary tumorigenesis.  
Cancer Res 2007, 67:4869-4877.
19. Noel A, De Pauw-Gillet MC, Purnell G, Nusgens B, Lapiere CM, Foidart JM: 
Enhancement of tumorigenicity of human breast adenocarcinoma 
cells in nude mice by matrigel and fibroblasts.  Br J Cancer 1993, 
68:909-915.
20. Guo X, Oshima H, Kitmura T, Taketo MM, Oshima M: Stromal fibroblasts 
activated by tumor cells promote angiogenesis in mouse gastric 
cancer.  J Biol Chem 2008, 283:19864-19871.
21. Gabbiani G, Kapanci Y, Barazzone P, Franke WW: Immunochemical 
identification of intermediate-sized filaments in human neoplastic 
cells. A diagnostic aid for the surgical pathologist.  Am J Pathol 1981, 
104:206-216.
22. Strutz F, Okada H, Lo CW, Danoff T, Carone RL, Tomaszewski JE, Neilson EG: 
Identification and characterization of a fibroblast marker: FSP1.  J Cell 
Biol 1995, 130:393-405.
23. Iwano M, Fischer A, Okada H, Plieth D, Xue C, Danoff TM, Neilson EG: 
Conditional abatement of tissue fibrosis using nucleoside analogs to 
selectively corrupt DNA replication in transgenic fibroblasts.  Mol Ther 
2001, 3:149-159.
24. Christiansen VJ, Jackson KW, Lee KN, McKee PA: Effect of fibroblast 
activation protein and [alpha]2-antiplasmin cleaving enzyme on 
collagen types I, III, and IV.  Arch Biochem Biophys 2007, 457:177-186.
25. Aggarwal S, Brennen WN, Kole TP, Schneider E, Topaloglu O, Yates M, 
Cotter RJ, Denmeade SR: Fibroblast activation protein peptide 
substrates identified from human collagen I derived gelatin cleavage 
sites.  Biochemistry 2008, 47:1076-1086.
26. Cohen SJ, Alpaugh RK, Palazzo I, Meropol NJ, Rogatko A, Xu Z, Hoffman JP, 
Weiner LM, Cheng JD: Fibroblast activation protein and its relationship 
to clinical outcome in pancreatic adenocarcinoma.  Pancreas 2008, 
37:154-158.
27. Garin-Chesa P, Old LJ, Rettig WJ: Cell surface glycoprotein of reactive 
stromal fibroblasts as a potential antibody target in human epithelial 
cancers.  PNAS 1990, 87:7235-7239.
28. Goscinski MA, Suo Z, Flørenes VA, Vlatkovic L, Nesland JM, Giercksky KE: 
FAP-alpha and uPA show different expression patterns in premalignant 
and malignant esophageal lesions.  Ultrastruct Pathol 2008, 32:89-96.
Received: 8 February 2010 Accepted: 8 June 2010 
Published: 8 June 2010
This article is available from: http://www.jeccr.com/content/29/1/66 © 2010 Zhi et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Journal of Experimental & Clinical Cancer Research 2010, 29:66Zhi et al. Journal of Experimental & Clinical Cancer Research 2010, 29:66
http://www.jeccr.com/content/29/1/66
Page 8 of 8
29. Henry LR, Lee HO, Lee JS, Klein-Szanto A, Watts P, Ross EA, Chen WT, 
Cheng JD: Clinical implications of fibroblast activation protein in 
patients with colon cancer.  Clin Cancer Res 2007, 13:1736-1741.
30. Scanlan MJ, Raj BK, Calvo B, Garin-Chesa P, Sanz-Moncasi MP, Healey JH, 
Old LJ, Rettig WJ: Molecular cloning of fibroblast activation protein a, a 
member of the serine protease family selectively expressed in stromal 
fibroblasts of epithelial cancers.  PNAS 1994, 91:5657-5661.
31. Santos AM, Jung J, Aziz N, Kissil JL, Puré E: Targeting fibroblast activation 
protein inhibits tumor stromagenesis and growth in mice.  J Clin Invest 
2009, 119:3613-3625.
32. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, 
Carey VJ, Richardson AL, Weinberg RA: Stromal fibroblasts present in 
invasive human breast carcinomas promote tumor growth and 
angiogenesis through elevated SDF-1/CXCL12 secretion.  Cell 2005, 
121:335-348.
33. Ao M, Franco OE, Park D, Raman D, Williams K, Hayward SW: Crosstalk 
between paracrine-acting cytokine and chemokine pathways 
promotes malignancy in benign human prostatic epithelium.  Cancer 
Res 2007, 67:4244-4253.
34. Vindrieux D, Escobar P, Lazennec G: Emerging roles of chemokines in 
prostate cancer.  Endocr Relat Cancer 2009, 16:663-673.
35. Tuxhorn JA, McAlhany SJ, Yang F, Dang TD, Rowley DR: Inhibition of 
transforming growth factor-beta activity decreases angiogenesis in a 
human prostate cancer-reactive stroma xenograft model.  Cancer Res 
2002, 62:6021-6025.
36. Shimoda M, Mellody KT, Orimo A: Carcinoma-associated fibroblasts are 
a rate-limiting determinant for tumour progression.  Semin Cell Dev Biol 
2010, 21:19-25.
37. de la Peña S, L Sampieri C, León-Córdoba K: Matrix metalloproteases as 
molecular markers in gastric cancer.  Med Clin (Barc) 2010, 134:123-126.
38. Ge J, Chen Z, Wu S, Chen J, Li X, Li J, Yin J, Chen Z: Expression levels of 
insulin-like growth factor-1 and multidrug resistance-associated 
protein-1 indicate poor prognosis in patients with gastric cancer.  
Digestion 2009, 80:148-158.
39. Gao P, Zhou GY, Zhang QH, Su ZX, Zhang TG, Xiang L, Wang Y, Zhang SL, 
Mu K: Lymphangiogenesis in gastric carcinoma correlates with 
prognosis.  J Pathol 2009, 218:192-200.
doi: 10.1186/1756-9966-29-66
Cite this article as: Zhi et al., Cancer-associated fibroblasts are positively cor-
related with metastatic potential of human gastric cancers Journal of Experi-
mental & Clinical Cancer Research 2010, 29:66